Skip to main content

Media

Angel Biotechnology up 18.5 per cent after Russian JV deal announced

Biopharmaceutical contract manufacturer Angel Biotechnology Holdings (LON:ABH) is forming a joint venture company with Russian pharmaceutical firm Materia Medica Holding aimed at allowing Angel to continue the expansion of its core business. Shares in the firm were up 18.5 per cent to 0.2725 pence by mid-morning in response to the news.

The new joint venture, 51 per cent-owned by MMH, will commission new product programmes and manage their production in a dedicated ‘good manufacturing practice’ facility that will be operated by Angel on behalf of MMH.

Angel will increase the size of its GMP facility at Cramlington in order to customise a new dedicated area that will be allocated to the joint venture for the manufacture of MMH products. MMH wil fund the cost of the work and provide funding for the purchase of any necessary capital equipment.

The firm added that the arrangement between it and MMH will be reviewed after five years and that it understand that MMH will require “a minimum seven products” to be manufactured in the first three to five years.

“This deal opens a new and important chapter of the continuing growth and development of Angel, cementing an alliance between the company and its major customer and giving greater visibility of work and income well into the future,” said Dr Paul Harper, Angel’s executive chairman.

Commenting on the news, independent broker Daniel Stewart said that Angel’s links with Materia Medica have been strong since its incorporation, but that the new JV and associated seven-contract deal solidifies the relationship further. “We estimate this partnership has the capacity to deliver revenues of around £1.5 million per annum,” said the broker, which added: “There will always be a market for companies putting treatments through clinical trials and Angel is well positioned to exploit this.”

Daniel Stewart has set a target of 0.47 pence each for Angel’s shares.